I often think some 'investors' are too stupid to own shares in pharmaceutical start ups. By definition they are pre-revenue until clinical trials are complete and a product is allowed to be sold to the public. Clarity is still at least a year away from that. So they can only 'trade' at a loss until revenue commences, but once approved for sale the R&D investment will be repaid handsomely. They have $120m in cash in the bank, so rudimentary arithmetic says that they can withstand another 4 years of losses before needing more cash, but products are on track to go to market in about 12 months, generating massive revenue.
Based on the FTDs being issued by the FDA, Clarity is one of the most successful pharmaceutical companies ever! So the current share price really doesn't do them justice nor reflect their objective value. As a longterm shareholder I am still well in the black from the $1.80 IPO price and have no plans to sell! In fact I'm expecting the share price to get back to $9 by Sepember and to get to $20 once products are earning revenue.
CU6 Price at posting:
$2.97 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)